- Leqembi - ALZFORUM
Lecanemab slowed decline on the CDR-SB by 27 percent compared to placebo at 18 months Key secondary endpoints, including the ADAS-Cog14, ADCOMS, and ADCS MCI-ADL, all showed a similar slowing of decline Two-thirds of the treated group became PET-amyloid negative at 18 months
- Finally: Big Win on All Outcomes for Lecanemab in Phase 3 . . . - ALZFORUM
Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab The drug slowed decline on the primary endpoint, CDR-SB, by 27 percent over 18 months, and also nudged down decline on all secondary clinical endpoints The
- Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ . . .
Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U S marketing approval What distinguished the successful ones? In a preprint posted to bioRxiv on October 12, scientists led
- Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
Lecanemab Secondary Prevention Study Now Fully Enrolled Lecanemab was approved for people with mild cognitive impairment or mild dementia due to Alzheimer’s, but trial data show it works better if given earlier The AHEAD 3-45 study, a pair of sister trials, homes in on this point, testing lecanemab’s ability to delay the onset of symptoms
- Leqembi Maintenance Dosing Approved in the U. S. | ALZFORUM
The U S Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27 Previously, the label called for biweekly IV dosing The new decision allows physicians to consider transitioning patients to monthly dosing once they have completed
- Questions, Questions for Donanemab, Lecanemab - ALZFORUM
For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they modeled how plaque clearance relates to cognitive benefit in an attempt to address a nagging question about this relationship See, You’re Negative
- Donanemab Clinical Use Growing in U. S. , Rejected in Europe
Like lecanemab before it, donanemab’s path to market has been slow and rocky In the U S , the antibody received Food and Drug Administration approval about nine months ago, but only a few hundred people are on it yet In Europe, the Committee for Medicinal Products for Human Use on Thursday recommended against approving donanemab for
- Rising Leqembi Prescriptions Are Straining Clinic Capacity
As lecanemab use ramps up, clinicians expect demand to overwhelm the staff at most memory clinics At WashU’s Knight Alzheimer Disease Research Center—one of the larger centers in the country—the staff comprises 12 physicians and four physician assistants or nurse practitioners
|